{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:26:09Z","timestamp":1789601169971,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and body weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A search formula was written using search terms such as \u201ctirzepatide,\u201d \u201coverweight,\u201d and \u201cobesity.\u201d A comprehensive search was conducted on databases such as PubMed, Cochrane Library, Embase, and Web of Science using a computer. Random controlled trial (RCT) literature was selected based on inclusion and exclusion criteria. After extracting the data, literature bias risk assessment and meta-analysis were conducted using RevMan 5.4 software. The search deadline is from the establishment of each database to May 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 12 randomized controlled trials were included, with a total of 11,758 patients. Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI (body mass index) of patients [MD\u2009=\u2009\u22121.71, 95% CI (\u22122.46, \u22120.95), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001], [MD\u2009=\u2009\u22123.99, 95% CI (\u22123.69, \u22122.45), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001], [MD\u2009=\u2009\u22124.02, 95% CI (\u22124.72, \u22123.31), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u200900.00001]. In terms of decreasing waist circumference, tirzepatide has a more significant advantage [MD\u2009=\u2009\u22124.08, 95% CI (\u22125.77, \u22122.39), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001], [MD\u2009=\u2009\u22127.71, 95% CI (\u221210.17, \u22125.25), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001], [MD\u2009=\u2009\u22129.15, 95% CI (\u221210.02, \u22128.29), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001]. In the analysis of body weight, tirzepatide showed a more significant reduction effect compared to the control group [MD\u2009=\u2009\u22125.65, 95% CI (\u22127.47, \u22123.82), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001], [MD\u2009=\u2009\u221210.06, 95% CI (\u221212.86, \u22127.25), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001], [MD\u2009=\u2009\u221210.63, 95% CI (\u221212.42, \u22128.84), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001]. In comparison with placebo, tirzepatide had a prominent advantage in weight loss \u226520% and \u226525% [RR\u2009=\u200930.43, 95% CI (19.56, 47.33), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001], [RR\u2009=\u200937.25, 95% CI (26.03, 53.30), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.00001]. Subgroup analysis showed a dose-dependent therapeutic effect. In terms of safety, compared with the placebo and insulin groups, the incidence of gastrointestinal adverse reactions was markedly higher in the tirzepatide group, slightly higher to the GLP-1 RAs group. The hypoglycemic (&amp;lt;70\u2009mg\/dL) risk of tirzepatide was slightly higher to that of placebo and GLP-1 RAs, but significantly lower than that of the insulin group [RR\u2009=\u20090.46, 95% CI (0.36, 0.58), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001]. The incidence of other adverse events, including pancreatitis, cholecystitis, major adverse cardiovascular events-4, hypersensitivity reactions, and neoplasms did not show significant statistical differences compared to the control group (<jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Overall, its efficacy is significant and its safety is high.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1277113","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:35:06Z","timestamp":1706675706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Wenting","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"804719","DOI":"10.3389\/fnut.2022.804719","article-title":"Advances in phenotyping obesity and in its dietary and pharmacological treatment: a narrative review","volume":"9","author":"Pujia","year":"2022","journal-title":"Front Nutr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Bhupathiraju","year":"2016","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 Aha\/Acc\/Tos guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(11)60105-0","article-title":"Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies","volume":"377","author":"Wormser","year":"2011","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/1471-2458-12-631","article-title":"Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease","volume":"12","author":"Siren","year":"2012","journal-title":"BMC Public Health"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3407306","article-title":"The impact of obesity on the cardiovascular system","volume":"2018","author":"Csige","year":"2018","journal-title":"J Diabetes Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"105782","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","volume":"171","author":"Lazzaroni","year":"2021","journal-title":"Pharmacol Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 esc guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the Easd","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/archdischild-2020-319809","article-title":"Glucagon-like peptide 1 (Glp-1) analogues and weight loss","volume":"105","year":"2020","journal-title":"Arch Dis Child"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual Gip and Glp-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (Gip and Glp-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1194\/jlr.M006841","article-title":"Gip increases human adipocyte Lpl expression through Creb and Torc2-mediated trans-activation of the Lpl gene","volume":"51","author":"Kim","year":"2010","journal-title":"J Lipid Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrn.2018.8","article-title":"Signalling from the periphery to the brain that regulates energy homeostasis","volume":"19","author":"Kim","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/d41573-022-00103-4","article-title":"Lilly\u2019s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"170206","DOI":"10.1016\/j.peptides.2019.170206","article-title":"Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion","volume":"125","author":"Reimann","year":"2020","journal-title":"Peptides"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (Surmount-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"ref25","volume-title":"Obesity: Identification, assessment and Management of Overweight and Obesity in children, Young people and adults: Partial update of Cg43[M]","author":"Uk","year":"2014"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of Ly3298176, a novel dual Gip and Glp-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","volume":"22","author":"Frias","year":"2020","journal-title":"Diab Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (Surpass-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"del Prato","year":"2021","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without Sglt2 inhibitors in patients with type 2 diabetes (Surpass-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual Gip and Glp-1 receptor agonist tirzepatide in patients with type 2 diabetes (Surpass-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the Surpass-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (Surpass J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the Surpass-Ap-combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/ph14100991","article-title":"Efficacy and safety of Tirzepatide in patients with type 2 diabetes mellitus: a systematic review and Meta-analysis of randomized phase ii\/iii trials","volume":"14","author":"Bhagavathula","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e285197","DOI":"10.1371\/journal.pone.0285197","article-title":"Weight loss efficiency and safety of tirzepatide: a systematic review","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting Glp-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"100991","DOI":"10.1016\/j.molmet.2020.100991","article-title":"Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists","volume":"37","author":"Lucey","year":"2020","journal-title":"Mol Metab"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s10787-023-01239-4","article-title":"Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"Glp-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of Tirzepatide, dual Gip and Glp-1 receptor agonist, in the Management of Type 2 diabetes: the Surpass clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (Sglt-2) inhibitors and glucagon-like peptide-1 (Glp-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"Ly3298176, a novel dual Gip and Glp-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/metabo10020048","article-title":"Metabolically healthy obesity-heterogeneity in definitions and unconventional factors","volume":"10","author":"Brandao","year":"2020","journal-title":"Meta"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2023.05.012","article-title":"Tirzepatide and potential use for metabolically healthy obesity","volume":"113","author":"Copur","year":"2023","journal-title":"Eur J Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejim.2023.02.025","article-title":"Metabolically healthy obesity: misleading phrase or healthy phenotype?","volume":"111","author":"Tanriover","year":"2023","journal-title":"Eur J Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis","volume":"47","author":"Tan","year":"2023","journal-title":"Int J Obes"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"m997","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.7570\/jomes22012","article-title":"The upcoming weekly tides (Semaglutide vs. Tirzepatide) against obesity: step or Surpass?","volume":"31","author":"Jung","year":"2022","journal-title":"J Obes Metab Syndr"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1277113\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:35:09Z","timestamp":1706675709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1277113\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":52,"alternative-id":["10.3389\/fpubh.2024.1277113"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1277113","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"article-number":"1277113"}}